Literature DB >> 18986331

Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels.

Jiong-Yu Hu1, Jian Han, Zhi-Gang Chu, Hua-Pei Song, Dong-Xia Zhang, Qiong Zhang, Yue-Sheng Huang.   

Abstract

1. Astragaloside IV (AST-IV) is purified from a natural plant product. Previous studies have shown that AST-IV has anti-oxidant activity. In the present study, we investigated the effect and mechanism of action AST-IV on rat cardiomyocytes subjected to hypoxic conditions (up to 12 h). 2. Cardiomyocytes were prepared from neonatal rats and cultured under normoxic or hypoxic conditions in the absence or presence of AST-IV (12.5, 25 or 50 microg/mL). Cell viability, malondialdehyde (MDA) levels, activity and expression of superoxide dismutase (SOD)-1 (mRNA and protein levels determined by reverse transcription-polymerase chain reaction and western blotting, respectively) and reactive oxygen species (ROS; determined by 2',7'-dichlorodihydrofluorescein diacetate) were investigated under these culture conditions. Intracellular localization of AST-IV was tested using fluorescein isothiocyanate-labelled AST-IV. 3. Hypoxic culture reduced the viability of cardiomyocytes, which was improved following treatment with 25 or 50 microg/mL AST-IV. Under hypoxic conditions, MDA levels were double those under control conditions. Astragaloside IV (25 and 50 microg/mL) dose-dependently reduced the increase in MDA seen in hypoxic cardiomyocytes. 4. Fluorescein isothiocyanate-labelled AST-IV entered cardiomyocytes and was localized mainly within the cytoplasm. 5. Under hypoxic conditions, SOD-1 activity was decreased, but mRNA and protein expression increased, compared with normoxia. Following treatment with 25 microg/mL AST-IV, SOD-1 activity and expression were increased under both normoxic and hypoxic conditions. The ROS scavenging effect of AST-IV was abolished in the presence of the SOD inhibitor sodium diethyl dithiocarbamate (25 micromol/L). 6. These in vitro results show that AST-IV protects cardiomyocytes from oxidative stress-mediated injury under hypoxic conditions. A major part of this action is achieved by upregulation of SOD-1 content and activity within the cell cytoplasm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986331     DOI: 10.1111/j.1440-1681.2008.05059.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  15 in total

1.  Astragaloside IV attenuates orbital inflammation in Graves' orbitopathy through suppression of autophagy.

Authors:  Hong Li; Yali Zhang; Jie Min; Long Gao; Ren Zhang; Yucheng Yang
Journal:  Inflamm Res       Date:  2017-11-10       Impact factor: 4.575

2.  Astragaloside IV rescues MPP+-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A.

Authors:  Yue Liu; Li Chong; Xiaoqing Li; Peng Tang; Peng Liu; Chen Hou; Xin Zhang; Rui Li
Journal:  Exp Ther Med       Date:  2017-07-25       Impact factor: 2.447

3.  Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis.

Authors:  Jing Zhao; Pengyuan Yang; Fan Li; Lin Tao; Hong Ding; Yaocheng Rui; Zhiwei Cao; Weidong Zhang
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

4.  Astragaloside IV inhibits oxidative stress-induced mitochondrial permeability transition pore opening by inactivating GSK-3β via nitric oxide in H9c2 cardiac cells.

Authors:  Yonggui He; Jinkun Xi; Huan Zheng; Yidong Zhang; Yuanzhe Jin; Zhelong Xu
Journal:  Oxid Med Cell Longev       Date:  2012-09-25       Impact factor: 6.543

5.  Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy.

Authors:  L Q Meng; J W Tang; Y Wang; J R Zhao; M Y Shang; M Zhang; S Y Liu; L Qu; S Q Cai; X M Li
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

6.  Remission of CVB3-induced myocarditis with Astragaloside IV treatment requires A20 (TNFAIP3) up-regulation.

Authors:  Jun Gui; Ruizhen Chen; Wei Xu; Sidong Xiong
Journal:  J Cell Mol Med       Date:  2015-03-01       Impact factor: 5.310

7.  Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells.

Authors:  Yao Lu; Su Li; Hengfang Wu; Zhiping Bian; Jindan Xu; Chunrong Gu; Xiangjian Chen; Di Yang
Journal:  Int J Mol Med       Date:  2015-09-15       Impact factor: 4.101

8.  Astragaloside IV ameliorates renal injury in db/db mice.

Authors:  Huili Sun; Wenjing Wang; Pengxun Han; Mumin Shao; Gaofeng Song; Heng Du; Tiegang Yi; Shunmin Li
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

9.  A comparative study on inhibition of total astragalus saponins and astragaloside IV on TNFR1-mediated signaling pathways in arterial endothelial cells.

Authors:  Qin-she Liu; Hai-fang Wang; An-ke Sun; Xue-ping Huo; Jin-lian Liu; Shu-hui Ma; Ning Peng; Jun Hu
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

Review 10.  Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic.

Authors:  Ping Liu; Haiping Zhao; Yumin Luo
Journal:  Aging Dis       Date:  2017-12-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.